Bempedoic acid adherence, persistence, and effect in adults in Italy
Official title: Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy
Run by Federico II University · NCT07374861 · Data updated 2026-11-12
This project will see how well bempedoic acid works and how consistently adults with high cholesterol in Italy take it.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | Federico II University Academic / other |
| Locations | 1 site (Naples, Napoli) |
| Status | Recruiting |
| Started | November 4, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2028 |
| Registry record updated | January 29, 2026 |
| Trial ID | NCT07374861 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–80 in Italy who are currently taking bempedoic acid and willing to give informed consent.
✕Probably not a fit
People not taking bempedoic acid, individuals under 18 or over 80, or those who decline consent are not eligible and will not benefit from this study's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter observational project will follow adults in Italy who are already being treated with bempedoic acid to document medication adherence, persistence, and changes in lipid levels in routine care. Investigators will collect clinical records, laboratory lipid measurements, and adherence information such as prescription refills or patient reports. The study excludes people under 18 or over 80 and requires informed consent from participants. Data will be analyzed to describe real-world persistence over time and the associated impact on cholesterol control.
Why it matters
Potential benefit: If successful, the findings could help clinicians understand real-world adherence and effectiveness of bempedoic acid and guide strategies to improve cholesterol control.
How similar studies have gone: Randomized trials have shown bempedoic acid lowers LDL cholesterol and improves outcomes, while real-world adherence studies for this drug are limited, so this project adds observational data from routine care.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients under Bempedoic acid treatment Exclusion Criteria: * Age \< 18 years o \> 80 years * Patients who refuse to participate and to sign informed consent
Where it's running
-
Federico II University of Naples, Department of Advanced Biomedical Sciences
Naples, Napoli, Italy Recruiting
Study contacts
- Study coordinator: Pasquale Perrone Filardi
- Email: fpperron@unina.it
- Phone: +39081/7462224
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
VERVE-102 for adults with or at high risk for heart disease
This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.
-
Enlicitide (MK-0616) for adults with high cholesterol in India
This study tests whether enlicitide helps lower bad cholesterol (LDL-C) compared with placebo in adults with hyperlipidemia/hypercholesterolemia.
-
Pemafibrate in people with high cholesterol not fully controlled by statins
This study tests whether taking Pemafibrate at 0.2 mg or 0.4 mg daily for 12 weeks helps people with high cholesterol who still don’t respond well to statins, compared with a placebo.
-
Dual PCSK9 Inhibition in secondary prevention for high LDL-C with statin intolerance
This study tests whether combining inclisiran and alirocumab lowers LDL cholesterol better than either drug alone in people with ASCVD who can’t tolerate statins.
-
Moderate-Intensity Statin + Ezetimibe vs High-Intensity Statin in CKD with ASCVD
In adults with chronic kidney disease and established cardiovascular disease, this study tests whether a moderate-intensity statin plus ezetimibe can match the benefits of a high-intensity statin alone over three years.
-
Corn oil versus avocado oil effects on cardiometabolic risk factors
This trial will test whether following controlled diets containing either corn oil or avocado oil for 21 days changes cardiometabolic risk factors in adults with mildly to moderately high non‑HDL cholesterol.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.